Neisseria meningitidis Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Neisseria meningitidis Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.
The Neisseria meningitidis Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Neisseria meningitidis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Neisseria meningitidis Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 40 molecules, with 33 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Neisseria meningitidis Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Neisseria meningitidis Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Neisseria meningitidis Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AIM Vaccine Co LtdAlopexx Inc
Beijing Minhai Biotechnology Co Ltd
Butantan Institute
CanSino Biologics Inc
Children's Hospital Oakland Research Institute
Chongqing Zhifei Biological Products Co Ltd
Eubiologics Co Ltd
GSK plc
Hilleman Laboratories Pvt Ltd
ImmunoBiology Ltd
Intravacc BV
Inventprise LLC
Lanzhou Institute of Biological Products Co Ltd
Neoculi Pty Ltd
Omvax Inc
Pfizer Inc
Sanofi
Sanofi Pasteur SA
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Sinovac Biotech Ltd
SPbNIIVS FMBA of Russia
Stockholm University
Suzhou Weichao Biotechnology Co Ltd
University of Oxford
University of Southampton
Wellstat Vaccines LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Neisseria meningitidis Infections reports